Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

GSK Reports 2Q Profit of $1.8B

July 26, 2011 7:13 am | News | Comments

A big reduction in administrative costs and strong sales in Japan helped GlaxoSmithKline PLC return to profit in the second quarter of the year. The pharmaceutical company reported a profit of $1.8 billion in the second quarter.


UCL Business PLC and NCYPE Agreement for Epistatus

July 25, 2011 12:31 pm | News | Comments

Special Products Limited has signed a commercialisation agreement with UCL Business PLC (UCLB) and the National Centre for Young People with Epilepsy (NCYPE) in preparation for the marketing of the company’s epilepsy treatment, Epistatus, as a licensed medicine.


SuperGen Completes Acquires Astex Therapeutics

July 25, 2011 12:27 pm | News | Comments

SuperGen Inc. has acquired Astex Therapeutics Limited.


Leukocare AG and Sanofi Pasteur Sign Agreement for Vaccine Stabilization

July 25, 2011 12:25 pm | News | Comments

Leukocare  AG announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi.


JHP Pharmaceuticals Enters Agreement for Drug

July 25, 2011 12:20 pm | News | Comments

JHP Pharmaceuticals has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.


Anavex 2-73 in Amyloid and Tau Pathology

July 25, 2011 12:16 pm | News | Comments

Anavex Life Sciences Corp. conducted a study entitled, “The novel aminotetrahydrofuran derivative Anavex 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.”


New Weapon in War Against Food Poisoning

July 25, 2011 12:06 pm | News | Comments

Food-poisoning has been revealed as a new target for nitric oxide in studies of how it inhibits the growth of Salmonella.


Genetic Variations Predict Cancer Risk

July 25, 2011 12:00 pm | News | Comments

A genome-wide association study has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.


Breast Cancer Cell Lines

July 25, 2011 8:14 am | Product Releases | Comments

Sigma Life Science announced the expansion of its CompoZr Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knock-out and knock-in cell lines for drug discovery and research.


Structural Review Software

July 25, 2011 8:09 am | Product Releases | Comments

Optibrium has launched a new version of StarVue, its innovative free desktop application that enables scientists to quickly and conveniently view sets of compound structures and related data.


Agilent Supplies Instrumentation for New Screening Center

July 25, 2011 8:01 am | News | Comments

Agilent Technologies Inc. and A*STAR’s Experimental Therapeutics Centre launched a drug-screening platform within ETC’s Singapore Screening Centre. A*Star selected Agilent to provide a full spectrum of automation technologies to biomedical researchers.


Patent Cliff Winners and Losers

July 25, 2011 7:56 am | by Linda A. Johnson | News | Comments

Those who help foot the bills for prescription drugs - patients, taxpayers, employers and some labor unions - won't be the only ones to benefit as dozens of popular brand-name pills get generic competition over the next several years.


Sublinox Approved in Canada

July 25, 2011 7:50 am | News | Comments

Valeant Pharmaceuticals International Inc. said that Canadian regulators have approved its insomnia treatment Sublinox, and it expects to launch the product in the fourth quarter in Canada.


FDA Approves Subcutaneous Gammagard

July 25, 2011 7:48 am | News | Comments

Baxter International Inc. announced that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% for patients with primary immunodeficiency.


AVI-4658 Restores Dystrophin Expression

July 25, 2011 7:43 am | News | Comments

A new study shows it is possible, using a targeted antisense therapy called AVI-4658, to restore expression of a key protein that is lacking in patients with the seriously debilitating condition Duchenne muscular dystrophy.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.